stoxline Quote Chart Rank Option Currency Glossary
  
Arrowhead Pharmaceuticals, Inc. (ARWR)
25.5  1.71 (7.19%)    06-21 16:00
Open: 23.47
High: 25.705
Volume: 3,148,368
  
Pre. Close: 23.79
Low: 23.47
Market Cap: 3,167(M)
Technical analysis
2024-06-21 4:50:40 PM
Short term     
Mid term     
Targets 6-month :  31.36 1-year :  36.62
Resists First :  26.85 Second :  31.36
Pivot price 24.79
Supports First :  24.06 Second :  22.35
MAs MA(5) :  24.76 MA(20) :  24.55
MA(100) :  27.06 MA(250) :  28.6
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  42.5 D(3) :  45.9
RSI RSI(14): 54.3
52-week High :  39.83 Low :  20.67
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ARWR ] has closed below upper band by 30.9%. Bollinger Bands are 34% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 25.75 - 25.87 25.87 - 25.98
Low: 23.18 - 23.32 23.32 - 23.44
Close: 25.26 - 25.5 25.5 - 25.71
Company Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Headline News

Sun, 23 Jun 2024
Goldman Sachs Group Inc. Has $32.50 Million Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Sun, 23 Jun 2024
Goldman Sachs Group Inc. Raises Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Sun, 23 Jun 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 3.2% - Defense World

Fri, 21 Jun 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 3.2% - MarketBeat

Fri, 17 May 2024
Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point (ARWR) - Seeking Alpha

Thu, 09 May 2024
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 124 (M)
Held by Insiders 1.107e+008 (%)
Held by Institutions 4.4 (%)
Shares Short 8,870 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.5785e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 335.5 %
Return on Equity (ttm) -32.1 %
Qtrly Rev. Growth 3.547e+007 %
Gross Profit (p.s.) 0
Sales Per Share -105.78
EBITDA (p.s.) 0
Qtrly Earnings Growth -4.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -257 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -1
Price to Book value 0
Price to Sales -0.25
Price to Cash Flow 6.14
Stock Dividends
Dividend 0
Forward Dividend 9.34e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android